PortfoliosLab logoPortfoliosLab logo
UTHR vs. LQDA
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

UTHR vs. LQDA - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in United Therapeutics Corporation (UTHR) and Liquidia Corporation (LQDA). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, UTHR achieves a 12.85% return, which is significantly lower than LQDA's 79.33% return.


UTHR

1D
0.40%
1M
-7.86%
YTD
12.85%
6M
12.38%
1Y
71.99%
3Y*
35.66%
5Y*
25.60%
10Y*
16.80%

LQDA

1D
-1.10%
1M
46.77%
YTD
79.33%
6M
79.74%
1Y
243.23%
3Y*
93.10%
5Y*
84.80%
10Y*
*Multi-year figures are annualized to reflect compound growth (CAGR)

UTHR vs. LQDA - Yearly Performance Comparison


2026 (YTD)20252024202320222021202020192018
UTHR
United Therapeutics Corporation
12.85%38.09%60.46%-20.93%28.70%42.35%72.33%-19.12%-13.35%
LQDA
Liquidia Corporation
79.33%193.28%-2.24%88.85%30.80%65.08%-30.99%-80.26%95.14%

Correlation

The correlation between UTHR and LQDA is 0.09, meaning there is essentially no relationship between their price movements. Each responds to its own set of market drivers, making them strong candidates for combining in a diversified portfolio.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.09

Correlation (3Y)
Calculated over the trailing 3-year period

0.14

Correlation (5Y)
Calculated over the trailing 5-year period

0.13

Correlation (All Time)
Calculated using the full available price history since Jul 27, 2018

0.13

Fundamentals

Market Cap

UTHR:

$25.95B

LQDA:

$6.25B

EPS

UTHR:

$27.00

LQDA:

$0.24

PE Ratio

UTHR:

20.36

LQDA:

258.63

PS Ratio

UTHR:

8.27

LQDA:

20.03

PB Ratio

UTHR:

4.40

LQDA:

57.60

Total Revenue (TTM)

UTHR:

$3.17B

LQDA:

$288.07M

Gross Profit (TTM)

UTHR:

$2.74B

LQDA:

$275.77M

EBITDA (TTM)

UTHR:

$1.75B

LQDA:

$51.53M

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

UTHR vs. LQDA — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

UTHR
UTHR Risk / Return Rank: 8787
Overall Rank
UTHR Sharpe Ratio Rank: 8181
Sharpe Ratio Rank
UTHR Sortino Ratio Rank: 8787
Sortino Ratio Rank
UTHR Omega Ratio Rank: 8888
Omega Ratio Rank
UTHR Calmar Ratio Rank: 9090
Calmar Ratio Rank
UTHR Martin Ratio Rank: 8989
Martin Ratio Rank

LQDA
LQDA Risk / Return Rank: 9494
Overall Rank
LQDA Sharpe Ratio Rank: 9797
Sharpe Ratio Rank
LQDA Sortino Ratio Rank: 9393
Sortino Ratio Rank
LQDA Omega Ratio Rank: 9191
Omega Ratio Rank
LQDA Calmar Ratio Rank: 9595
Calmar Ratio Rank
LQDA Martin Ratio Rank: 9393
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

UTHR vs. LQDA - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for United Therapeutics Corporation (UTHR) and Liquidia Corporation (LQDA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


UTHRLQDADifference
Sharpe ratioReturn per unit of total volatility

-2.15

Sortino ratioReturn per unit of downside risk

-0.79

Omega ratioGain probability vs. loss probability

1.39

1.46

-0.06

Calmar ratioReturn relative to maximum drawdown

4.43

6.87

-2.44

Martin ratioReturn relative to average drawdown

11.34

15.23

-3.89

UTHR vs. LQDA - Sharpe Ratio Comparison

The current UTHR Sharpe Ratio is 1.45, which is lower than the LQDA Sharpe Ratio of 3.61. The chart below compares the historical Sharpe Ratios of UTHR and LQDA, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Sharpe Ratios by Period


UTHRLQDADifference

Sharpe Ratio (1Y)

Calculated over the trailing 1-year period

1.45

3.61

-2.15

Sharpe Ratio (5Y)

Calculated over the trailing 5-year period

0.73

1.16

-0.43

Sharpe Ratio (10Y)

Calculated over the trailing 10-year period

0.48

Sharpe Ratio (All Time)

Calculated using the full available price history

0.38

0.29

+0.10

Drawdowns

UTHR vs. LQDA - Drawdown Comparison

The maximum UTHR drawdown since its inception was -93.18%, roughly equal to the maximum LQDA drawdown of -93.87%. Use the drawdown chart below to compare losses from any high point for UTHR and LQDA.


Loading charts...

Drawdown Indicators


UTHRLQDADifference

Max Drawdown

Largest peak-to-trough decline

-93.18%

-93.87%

+0.69%

Max Drawdown (1Y)

Largest decline over 1 year

-16.35%

-35.66%

+19.31%

Max Drawdown (3Y)

Largest decline over 3 years

-33.00%

-46.80%

+13.80%

Max Drawdown (5Y)

Largest decline over 5 years

-33.00%

-55.36%

+22.36%

Max Drawdown (10Y)

Largest decline over 10 years

-55.56%

Current Drawdown

Current decline from peak

-7.86%

-1.10%

-6.76%

Average Drawdown

Average peak-to-trough decline

-35.31%

-69.69%

+34.38%

Ulcer Index

Depth and duration of drawdowns from previous peaks

6.37%

16.05%

-9.68%

Volatility

UTHR vs. LQDA - Volatility Comparison

The current volatility for United Therapeutics Corporation (UTHR) is 6.84%, while Liquidia Corporation (LQDA) has a volatility of 28.48%. This indicates that UTHR experiences smaller price fluctuations and is considered to be less risky than LQDA based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


UTHRLQDADifference

Volatility (1M)

Calculated over the trailing 1-month period

6.84%

28.48%

-21.64%

Volatility (6M)

Calculated over the trailing 6-month period

26.00%

47.89%

-21.89%

Volatility (1Y)

Calculated over the trailing 1-year period

49.78%

67.90%

-18.12%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

35.14%

73.61%

-38.47%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

35.08%

85.76%

-50.68%

Dividends

UTHR vs. LQDA - Dividend Comparison

Neither UTHR nor LQDA has paid dividends to shareholders.


Tickers have no history of dividend payments

Financials

UTHR vs. LQDA - Financials Comparison

This section allows you to compare key financial metrics between United Therapeutics Corporation and Liquidia Corporation. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.00200.00M400.00M600.00M800.00M20222023202420252026
781.50M
132.87M
(UTHR) Total Revenue
(LQDA) Total Revenue
Values in USD except per share items

UTHR vs. LQDA - Profitability Comparison

The chart below illustrates the profitability comparison between United Therapeutics Corporation and Liquidia Corporation over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

Gross Margin
Operating Margin
Net Margin
Quarterly
Annual

40.0%50.0%60.0%70.0%80.0%90.0%100.0%20222023202420252026
82.9%
99.4%
Portfolio components
UTHR - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, United Therapeutics Corporation reported a gross profit of 648.10M and revenue of 781.50M. Therefore, the gross margin over that period was 82.9%.

LQDA - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Liquidia Corporation reported a gross profit of 132.09M and revenue of 132.87M. Therefore, the gross margin over that period was 99.4%.

UTHR - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, United Therapeutics Corporation reported an operating income of 325.80M and revenue of 781.50M, resulting in an operating margin of 41.7%.

LQDA - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Liquidia Corporation reported an operating income of 61.50M and revenue of 132.87M, resulting in an operating margin of 46.3%.

UTHR - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, United Therapeutics Corporation reported a net income of 274.90M and revenue of 781.50M, resulting in a net margin of 35.2%.

LQDA - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Liquidia Corporation reported a net income of 52.86M and revenue of 132.87M, resulting in a net margin of 39.8%.


Frequently Asked Questions


UTHR and LQDA have a correlation of 0.09, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

LQDA has higher volatility (28.48%) compared to UTHR (6.84%). In terms of maximum drawdown, UTHR dropped -93.18% vs LQDA's -93.87%.

LQDA currently has the higher Sharpe Ratio (3.61 vs 1.45), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for UTHR and LQDA

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer